Compare TECX & HIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TECX | HIX |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 351.3M |
| IPO Year | 2018 | 1998 |
| Metric | TECX | HIX |
|---|---|---|
| Price | $20.05 | $3.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $71.00 | N/A |
| AVG Volume (30 Days) | 223.0K | ★ 424.9K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 40.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.60 | $3.41 |
| 52 Week High | $39.53 | $4.33 |
| Indicator | TECX | HIX |
|---|---|---|
| Relative Strength Index (RSI) | 29.83 | 25.59 |
| Support Level | $17.27 | N/A |
| Resistance Level | $23.61 | $4.04 |
| Average True Range (ATR) | 1.20 | 0.04 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 7.40 | 2.63 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.